Bridgeway Capital Management, LLC Aim Immuno Tech Inc. Transaction History
Bridgeway Capital Management, LLC
- $4.14 Billion
- Q2 2024
A detailed history of Bridgeway Capital Management, LLC transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 88,900 shares of AIM stock, worth $24,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,900
Previous 108,900
18.37%
Holding current value
$24,892
Previous $51,000
37.25%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AIM
# of Institutions
39Shares Held
8.44MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.08MShares$1.14 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$556,8370.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$195,5140.0% of portfolio
-
Geode Capital Management, LLC Boston, MA401KShares$112,2870.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny229KShares$64,0660.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $13.5M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...